Reader sentiment, not investment advice. One vote per visitor; click again to change it.
BDX is priced at $178.91 right now, down 0.05% on the session. That puts its market value at $48.73B, 311th largest among the 800 stocks we cover.
The stock's 52-week band runs $124.51 to $191.94, and the latest print sits 6.8% under the top end of it.
For the quarter ended Jun 2026 it reported $4.98B in revenue, up 5.4% from a year earlier, with $377.00M of net profit (a 4.2% margin).
The stock changes hands at 54.0 times trailing earnings, 28% above its five-year average of 42.2. The median for its industry group is 30.7.
9 analysts follow the stock and the average call is "buy". The mean target, $195.33, sits 9.2% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 4 factors below, ranked against the 800 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Higher trailing yield than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
9 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BDX is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-07-06, the strategy has returned 1524.8% (321.7% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $195.33, 9.2% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $225.00, so shares trade 20.5% below that estimate. On earnings multiple, it sits in the 92nd percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Quote as of Oct 1, 2026 12:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 800 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 54.0x earnings, BDX looks about mid-pack against the market, and trades 76% above the 30.7x median among Medical Instruments & Supplies names. The two comparisons do not always agree.
$178.91 is the latest print for BDX, a move of -0.05% against yesterday's close of $179.00. Today's low and high so far: $177.54 and $179.67.
Equity value comes to $48.73B at the current price. By that measure it is number 311 of the 800 names in our coverage.
Buyers pay 54.0 times the last twelve months of profit (EPS $5.82). Averaged over five years the multiple has been 42.2, and today's level ranks in the 92nd percentile of its own history.
The year's floor is $124.51 and the ceiling $191.94. Shares are 6.8% away from that ceiling.
It does. Payouts over the past twelve months work out to a 2.34% yield; the latest ex-dividend date was September 9, 2026.
Of 9 analysts, 56% say buy, 44% hold and 0% sell. Price targets average $195.33, with the most cautious at $180.00 and the most optimistic at $210.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on BDX.